Vanguard Fiduciary Trust
ENTA icon

Vanguard Fiduciary Trust’s Enanta Pharmaceuticals ENTA Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71M Buy
185,618
+9,762
+6% +$131K ﹤0.01% 2514
2026
Q1 		$2.22M Buy
+175,856
New +$2.36M ﹤0.01% 2509

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust's ENTA Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Enanta Pharmaceuticals (ENTA) stake by 5.6% in Q2 2026, buying an estimated $131K and bringing the position to 185,618 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

Vanguard Fiduciary Trust first reported a position in ENTA in Q1 2026 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Vanguard Fiduciary Trust held 185,618 shares of Enanta Pharmaceuticals worth $2.71M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 9,762 Enanta Pharmaceuticals shares in Q2 2026, an estimated $131K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2514 holding.
  • Vanguard Fiduciary Trust first reported a position in Enanta Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.